JPRN-jRCT1031200023招募中3 期
JCOG1901: An intergroup phase III study of combination therapy with everolimus and lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor - STARTER-NET
MIZUNO Nobumasa0 个研究点目标入组 250 人开始时间: 2020年4月27日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Histologically proven well-differentiated neuroendocrine tumor.
- •(2) HE-stained section and immunostained sections for Chromogranin A, Synaptophysin, and Ki-67 of the biopsy specimen, used for diagnosis in (1) is available for central pathological review.
- •(3) Primary tumor is located in the pancreas, duodenum (excluding the ampulla of Vater), jejunum, ileum, stomach, colon, or rectum.
- •(4) Unresectable primary tumor or unresectable recurrent tumor. In cases of recurrent tumors diagnosed in imaging studies, histologic reconfirmation of the recurrent location or the primary location in not mandatory if the diagnosis of the primary location is confirmed in the past.
- •(5) Non-functional neuroendocrine tumor.
- •(6) Satisfies either (i) or (ii).
- •(i) Ki-67 LI >= 5% and Ki-67 LI <= 20%
- •(ii) Ki-67 LI < 5% and diffuse bilobar liver metastases
- •(7) Mitotic count <= 20 /10HPF if mitotic count is obtained.
- •(8) Aged 20 years and older at the time of enrollment.
- •(9) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- •(10) Measurable region is not required.
- •(11) No history of systemic pharmacotherapy to NETs. Local treatments such as TACE(transcatheter arterial chemoembolization), TAE(transarterial embolization), RFA(radiofrequency ablation) are permissible.
- •(12) Adequate oral intake.
- •(13) Sufficient organ function. (Test results must be obtained within 14 days before enrollment.)
- •(i) Neutrophil count >= 1,200/mm3
- •(ii) Hemoglobin >= 8.0 g/dL(transfusion within 14 days before the blood test is not permissible)
- •(iii) Platelet count >= 75000 /mm3
- •(iv) Total bilirubin <= 2.0 mg/dL
- •(v) AST <= 100 U/L(<= 200 U/L if liver metastasis present)
- •(vi) ALT <= 100 U/L(<= 200 U/L if liver metastasis present)
- •(vii) Creatinine <= 1.5 mg/dL
- •(viii) Casual blood glucose <= 200 mg/dL
- •(14) Written informed consent.
排除标准
- •(1) History of synchronous or metachronous (within 2 years) malignancies with 5-year relative survivals of less than 95% at the time of diagnosis.)
- •(2) Active infection requiring systemic therapy other than viral hepatitis.
- •(3) Fever of higher than 38.0 degrees celsius at the time of enrollment.
- •(4) Pregnant, possibly pregnant, within 28 days after delivery, breastfeeding female or males expecting conception of their child.
- •(5) Psychiatric illnesses or symptoms affecting daily lives.
- •(6) Systemic administration of steroids or immunosuppressive agents.
- •(7) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT.
- •(8) Severe complications such as heart failure, renal failure, liver failure, hemorrhagic gastric ulcer, intestinal paralysis, or bowel obstruction.
- •(9) Unstable angina (diagnosis or worsening of chest pain within 6 weeks) or history of myocardial infarction within 6 months prior to enrollment.
- •(10) Uncontrollable diabetes (HbA1c > 8%).
- •(11) Positive for HIV antibodies.
- •(12) Administration of live attenuated vaccines within 7 days of enrollment.
研究者
相似试验
进行中（未招募）
1 期
A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancerAdvanced HR+ breast cancerMedDRA version: 21.1Level: LLTClassification code: 10072737Term: Advanced breast cancer Class: 10029104CTIS2023-509511-84-00ovartis Pharma AG251
已完成
不适用
Phase III randomized comparative study of combination therapy with CDDP and TS-1 vs. combination therapy with CDDP and Docetaxel in stage IIIB/IV non-small cell lung cancerStage IIIB/IV or ppstoperative recurrent non-small sell lung cancerJPRN-UMIN000000608The Tokyo cooperative oncology group600
进行中（未招募）
1 期
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancernresectable non metastatic stage III non small cell lung carcinoma eligible for concomitant radiochemotherapyMedDRA version: 9.1Level: HLGTClassification code 10038666Term: Respiratory and mediastinal neoplasms malignant and unspecifiedEUCTR2006-004726-91-FRCHRU de Lille246
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000633-40-DEJanssen-Cilag International NV300
进行中（未招募）
1 期
A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000633-40-PTJanssen-Cilag International NV300